Medicine & Life Sciences
Heart Failure
100%
Therapeutics
50%
Mortality
47%
Neoplasms
47%
Survival
46%
Confidence Intervals
37%
Early Detection of Cancer
37%
Population
36%
Heart
36%
Type 2 Diabetes Mellitus
35%
Odds Ratio
35%
Placebos
34%
Blood Pressure
32%
Randomized Controlled Trials
31%
Colorectal Neoplasms
31%
Depression
31%
Kidney
31%
Chronic Renal Insufficiency
30%
African Americans
30%
Breast Neoplasms
30%
Cardiovascular Diseases
27%
Radiotherapy
27%
Hypertension
26%
Hepatocellular Carcinoma
25%
Health
25%
Hydroxymethylglutaryl-CoA Reductase Inhibitors
25%
Pneumonia
25%
Exercise
25%
Mammography
24%
Incidence
24%
Lung Neoplasms
24%
Non-Small Cell Lung Carcinoma
23%
Hispanic Americans
23%
Veterans
23%
Clinical Trials
23%
Cohort Studies
22%
Hemodynamics
22%
Biomarkers
21%
Major Depressive Disorder
21%
Stroke
21%
Delivery of Health Care
21%
Serum
21%
Child
20%
Hospitalization
19%
Guidelines
19%
Outpatients
19%
Genes
19%
Myocardial Infarction
18%
Elderly
18%
Meta-Analysis
18%
Angiotensin-Converting Enzyme Inhibitors
18%
Physicians
18%
Kidney Diseases
18%
Cardiorespiratory Fitness
18%
HIV
17%
Alzheimer Disease
17%
Pharmaceutical Preparations
17%
Body Mass Index
16%
Logistic Models
16%
LCZ 696
16%
Safety
16%
Calcium
16%
Pediatrics
16%
African Continental Ancestry Group
15%
Costs and Cost Analysis
15%
Safety-net Providers
15%
Head and Neck Neoplasms
15%
Obesity
15%
Fibrosis
15%
Glomerular Filtration Rate
14%
Radiosurgery
14%
Sample Size
14%
Systematic Reviews
14%
Mutation
14%
Morbidity
14%
European Continental Ancestry Group
14%
Cancer Survivors
14%
Bipolar Disorder
14%
Colonoscopy
14%
Metabolic Syndrome
14%
Electronic Health Records
14%
Primary Health Care
14%
Drug Therapy
14%
Equipment and Supplies
13%
Prostatic Neoplasms
13%
Research Personnel
13%
Statistics
13%
Creatinine
13%
Insulin
13%
Stroke Volume
13%
Fats
13%
Quality of Life
13%
Datasets
13%
Atherosclerosis
12%
Medicare
12%
Recurrence
12%
Chronic Kidney Failure
12%
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
12%
Uterine Cervical Neoplasms
12%
Cost-Benefit Analysis
12%